BioLight Life Sciences Ltd (BOLT) - Net Assets
Based on the latest financial reports, BioLight Life Sciences Ltd (BOLT) has net assets worth ILA40.17 Million ILA (≈ $107.70K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA42.41 Million ≈ $113.71K USD) and total liabilities (ILA2.24 Million ≈ $6.01K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of BioLight Life Sciences Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA40.17 Million |
| % of Total Assets | 94.71% |
| Annual Growth Rate | 4.18% |
| 5-Year Change | -34.59% |
| 10-Year Change | 144.8% |
| Growth Volatility | 263.27 |
BioLight Life Sciences Ltd - Net Assets Trend (2005–2025)
This chart illustrates how BioLight Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is BioLight Life Sciences Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for BioLight Life Sciences Ltd (2005–2025)
The table below shows the annual net assets of BioLight Life Sciences Ltd from 2005 to 2025. For live valuation and market cap data, see market cap of BioLight Life Sciences Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ILA40.17 Million ≈ $107.70K |
+30.67% |
| 2024-12-31 | ILA30.74 Million ≈ $82.42K |
+1.46% |
| 2023-12-31 | ILA30.30 Million ≈ $81.24K |
-43.57% |
| 2022-12-31 | ILA53.69 Million ≈ $143.95K |
-12.58% |
| 2021-12-31 | ILA61.42 Million ≈ $164.66K |
+2.18% |
| 2020-12-31 | ILA60.11 Million ≈ $161.14K |
-11.80% |
| 2019-12-31 | ILA68.15 Million ≈ $182.70K |
-12.40% |
| 2018-12-31 | ILA77.80 Million ≈ $208.57K |
+868.70% |
| 2017-12-31 | ILA8.03 Million ≈ $21.53K |
-51.06% |
| 2016-12-31 | ILA16.41 Million ≈ $43.99K |
-65.13% |
| 2015-12-31 | ILA47.06 Million ≈ $126.17K |
+82.85% |
| 2014-12-31 | ILA25.74 Million ≈ $69.00K |
+16.41% |
| 2013-12-31 | ILA22.11 Million ≈ $59.27K |
-40.79% |
| 2012-12-31 | ILA37.34 Million ≈ $100.10K |
+58.57% |
| 2011-12-31 | ILA23.55 Million ≈ $63.13K |
+765.06% |
| 2010-12-31 | ILA2.72 Million ≈ $7.30K |
-79.54% |
| 2009-12-31 | ILA13.31 Million ≈ $35.68K |
+66.15% |
| 2006-12-31 | ILA8.01 Million ≈ $21.47K |
-54.75% |
| 2005-12-31 | ILA17.70 Million ≈ $47.46K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BioLight Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26169200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA22.62 Million | 65.75% |
| Other Comprehensive Income | ILA18.01 Million | 52.35% |
| Other Components | ILA255.46 Million | 742.54% |
| Total Equity | ILA34.40 Million | 100.00% |
BioLight Life Sciences Ltd Competitors by Market Cap
The table below lists competitors of BioLight Life Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
E-Pango SA
PA:ALAGO
|
$7.66 Million |
|
BPH Energy Ltd
AU:BPH
|
$7.66 Million |
|
NYRSTAR
F:3NY1
|
$7.67 Million |
|
T4F Entretenimento S.A
SA:SHOW3
|
$7.67 Million |
|
T.Krungthai Industries Public Company Limited
BK:TKT
|
$7.65 Million |
|
Equity Story Group Ltd
AU:EQS
|
$7.64 Million |
|
Cambium Bio Ltd
AU:CMB
|
$7.64 Million |
|
Ajooni Biotech Limited
NSE:AJOONI
|
$7.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioLight Life Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 26,879,000 to 34,404,000, a change of 7,525,000 (28.0%).
- Net loss of 11,727,000 reduced equity.
- New share issuances of 19,821,000 increased equity.
- Other comprehensive income increased equity by 1,884,000.
- Other factors decreased equity by 2,453,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-11.73 Million | -34.09% |
| Share Issuances | ILA19.82 Million | +57.61% |
| Other Comprehensive Income | ILA1.88 Million | +5.48% |
| Other Changes | ILA-2.45 Million | -7.13% |
| Total Change | ILA- | 28.00% |
Book Value vs Market Value Analysis
This analysis compares BioLight Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 54.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.89x to 54.38x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | ILA45.81 | ILA315.60 | x |
| 2013-12-31 | ILA9.19 | ILA315.60 | x |
| 2014-12-31 | ILA14.21 | ILA315.60 | x |
| 2015-12-31 | ILA13.87 | ILA315.60 | x |
| 2016-12-31 | ILA4.02 | ILA315.60 | x |
| 2017-12-31 | ILA1.89 | ILA315.60 | x |
| 2018-12-31 | ILA19.45 | ILA315.60 | x |
| 2019-12-31 | ILA15.16 | ILA315.60 | x |
| 2020-12-31 | ILA13.04 | ILA315.60 | x |
| 2021-12-31 | ILA13.24 | ILA315.60 | x |
| 2022-12-31 | ILA11.59 | ILA315.60 | x |
| 2023-12-31 | ILA6.41 | ILA315.60 | x |
| 2024-12-31 | ILA5.77 | ILA315.60 | x |
| 2025-12-31 | ILA5.80 | ILA315.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioLight Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-34.09%) is above the historical average (-61.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 2.43% | 1092.16% | 0.00x | 1.29x | ILA-1.73 Million |
| 2012 | -34.89% | -25684.62% | 0.00x | 1.09x | ILA-17.18 Million |
| 2013 | -149.82% | -22971.95% | 0.00x | 2.73x | ILA-20.09 Million |
| 2014 | -81.34% | -2455.05% | 0.02x | 1.42x | ILA-25.94 Million |
| 2015 | -55.59% | -1384.54% | 0.02x | 1.83x | ILA-22.72 Million |
| 2016 | -201.31% | -1033.82% | 0.06x | 3.26x | ILA-22.91 Million |
| 2017 | -282.95% | -1427.63% | 0.05x | 4.06x | ILA-17.87 Million |
| 2018 | 79.42% | 1773.39% | 0.04x | 1.10x | ILA57.15 Million |
| 2019 | -18.28% | -4239.39% | 0.00x | 1.09x | ILA-19.48 Million |
| 2020 | -22.60% | -43167.74% | 0.00x | 1.09x | ILA-19.30 Million |
| 2021 | 0.63% | 12733.33% | 0.00x | 1.06x | ILA-5.69 Million |
| 2022 | -14.76% | -12455.56% | 0.00x | 1.07x | ILA-13.16 Million |
| 2023 | -87.39% | -22050.85% | 0.00x | 1.12x | ILA-29.00 Million |
| 2024 | -26.57% | -3261.19% | 0.01x | 1.27x | ILA-9.83 Million |
| 2025 | -34.09% | 0.00% | 0.00x | 1.23x | ILA-15.17 Million |
Industry Comparison
This section compares BioLight Life Sciences Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $114,413,539
- Average return on equity (ROE) among peers: -124.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioLight Life Sciences Ltd (BOLT) | ILA40.17 Million | 2.43% | 0.06x | $7.66 Million |
| BioLine RX Ltd (BLRX) | $31.77 Million | -32.03% | 0.14x | $9.10 Million |
| Bonus Biogroup (BONS) | $84.43 Million | -106.69% | 0.24x | $123.99 Million |
| Can Fite Biopharma Ltd (CANF) | $2.44 Million | -516.99% | 2.35x | $5.56 Million |
| Clal Biotechnology Industries Ltd (CBI) | $808.20 Million | -3.45% | 0.28x | $12.61 Million |
| Compugen (CGEN) | $19.58 Million | -61.30% | 0.49x | $201.26 Million |
| DNA Biomed Solns (DNA) | $10.45 Million | 0.00% | 0.61x | $34.04 Million |
| Enlivex Therapeutics Ltd (ENLV) | $8.70 Million | -184.18% | 0.22x | $458.60K |
| Evogene (EVGN) | $56.88 Million | -46.07% | 0.26x | $4.88 Million |
| Kadimastem Ltd (KDST) | $7.28 Million | -173.39% | 0.71x | $22.18 Million |
About BioLight Life Sciences Ltd
BioLight Life Sciences Ltd. engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel. The company offers TeaRx, a diagnostic platform intended for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid; TeaRx D… Read more